Novo Nordisk launches Ozempic to manage Type 2 diabetes in India, Pg10

Key Highlights:

• Novo Nordisk launched Ozempic (injectable semaglutide) in India for managing Type 2 diabetes.
• Ozempic is a once-a-week injection available in three variants, with the starting dose of 0.25 mg priced at Rs 2,200 per week.
• The announcement was made on Friday by Novo Nordisk MD Vikrant Shrotriya.

Detailed Insights:

• Ozempic is a once-weekly GLP-1 RA (receptor agonist), used with diet and exercise for adults with uncontrolled Type 2 Diabetes Mellitus (T2DM).
• Other similar drugs include Wegovy, priced at Rs 2,712 (0.25 mg) and Rs 3,462 (0.5 mg) weekly, and Mounjaro at Rs 13,500 (2.5 mg) monthly.
• Type 2 diabetes is a chronic metabolic disorder characterized by high blood sugar, requiring comprehensive management through medication, diet, and exercise.

Key Concepts Involved:

• Semaglutide: A GLP-1 receptor agonist medication used to treat type 2 diabetes.
• GLP-1 RA (Receptor Agonist): A class of drugs that mimic the effects of GLP-1, a natural hormone that lowers blood sugar levels.
• Type 2 Diabetes Mellitus (T2DM): A chronic condition affecting how the body metabolizes sugar (glucose), a major source of energy.